Identification of Palmitoleic Acid Controlled by mTOR Signaling as a Biomarker of Polymyositis

Figure 4

Increased palmitoleic acid as a biomarker of PBMC in patients with polymyositis. (a) LC-MS results showed the increasing of palmitoleic acid level in PBMC of polymyositis (PM) patients compared with normal ones. Results come from 12 normals and 16 PM patients. Data represent mean with min. to max. . (b and c) Western blots and quantification showed that mTORC1 activity, indicated by pp70S6K1 and p4EBP1, was increased in PBMC of polymyositis (PM) patients compared with normal ones. Results are averages of nine independent experiments. Data represent mean ± SEM.

(a)

(b)

(c)